FATE FATE THERAPEUTICS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1434316 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-33.4%
TTM net income YoY20.3%
TTM EPS YoY22.6%
Revenue 3-yr CAGR-64.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,760.0%
Net margin-2,619.6%
FCF margin-2,249.4%
EBITDA margin-2,519.2%
Returns
ROE-67.8%
ROA-42.8%
ROIC (approx.)-73.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets44.2%
Debt / equity0.00x
Current ratio4.41x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue31.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $2.08M | $1.30M | $1.37M | $1.74M | $1.91M | $1.63M | $1.86M |
| R&D expense | $24.21M | $24.39M | $24.70M | $25.43M | $25.84M | $27.43M | $29.14M | $33.61M |
| SG&A expense | $8.03M | $8.83M | $9.60M | $10.66M | $10.64M | $11.45M | $13.77M | $15.26M |
| Operating income | -$32.25M | -$31.13M | -$33.00M | -$34.72M | -$34.73M | -$36.97M | -$41.28M | -$61.75M |
| Net income | -$30.69M | -$30.16M | -$31.21M | -$32.37M | -$32.25M | -$34.07M | -$37.62M | -$52.15M |
| EBITDA | -$29.57M | -$28.35M | -$30.08M | -$31.66M | -$31.51M | -$33.69M | -$37.95M | -$56.94M |
| EPS (basic) | -0.25 | -0.25 | -0.26 | — | -0.27 | -0.29 | -0.32 | — |
| EPS (diluted) | -0.25 | -0.25 | -0.26 | — | -0.27 | -0.29 | -0.32 | — |
| Weighted avg. shares (diluted) | 123.66M | 120.40M | 120.03M | — | 119.00M | 118.53M | 118.38M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $43.94M | $32.43M | $39.57M | $46.63M | $40.62M | $41.25M | $44.92M | $36.06M |
| Short-term investments | $95.19M | $121.34M | $135.25M | $157.03M | $174.80M | $181.58M | $195.50M | $243.01M |
| Receivables | $479,000 | $703,000 | $704,000 | $916,000 | $682,000 | $1.40M | $2.41M | $3.54M |
| Current assets | $144.26M | $157.95M | $179.53M | $208.70M | $221.25M | $230.40M | $248.22M | $291.91M |
| PP&E, net | $48.91M | $51.55M | $54.26M | $56.92M | $59.48M | $61.10M | $62.76M | $64.38M |
| Total assets | $238.28M | $260.10M | $284.92M | $318.94M | $343.67M | $371.63M | $398.67M | $440.69M |
| Current liabilities | $32.69M | $32.59M | $30.69M | $36.07M | $28.11M | $28.67M | $28.16M | $38.52M |
| Total liabilities | $105.24M | $106.67M | $105.21M | $111.75M | $109.61M | $110.27M | $110.26M | $121.97M |
| Shareholders' equity | $133.03M | $153.44M | $179.71M | $207.18M | $234.07M | $261.36M | $288.41M | $318.73M |
| Shares outstanding | 121.53M | 116.69M | 116.27M | 115.36M | 115.34M | 114.66M | 114.60M | 113.93M |
| Cash flow statement | ||||||||
| Operating cash flow | -$27.80M | -$23.40M | -$30.82M | -$23.31M | -$24.37M | -$24.59M | -$33.81M | -$27.80M |
| Capital expenditure | $0 | $80,000 | $239,000 | $1.19M | $2.20M | $1.36M | $1.20M | $98,000 |
| Free cash flow | -$27.80M | -$23.48M | -$31.06M | -$24.51M | -$26.58M | -$25.95M | -$35.01M | -$27.90M |
| Investing cash flow | $26.84M | $14.56M | $23.59M | $27.63M | $21.27M | $19.59M | $42.67M | $22.82M |
| Financing cash flow | $7.62M | — | — | $1.69M | $2.48M | $1.32M | $0 | $3.13M |
| Depreciation & amortization | $2.68M | $2.78M | $2.92M | $3.06M | $3.23M | $3.28M | $3.33M | $4.81M |
| Stock-based compensation | $2.70M | $3.52M | $3.93M | $5.53M | $4.86M | $7.15M | $7.38M | $9.12M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.